Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARE trial of regorafenib plus metronomic chemotherapy versus regorafenib alone in chemo-resistant metastatic colorectal cancer
2023-509761-21-00Phase 3Authorised
- Sponsor
- CHRU Nancy
- Start
- Mar 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of regorafenib, capecitabine, cyclophosphamide and aspirin in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by CHRU Nancy. Primary endpoint: Progression-free survival. Planned start Mar 2024; status: authorised.
02
Drugs
regorafenibcapecitabinecyclophosphamideaspirin
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2023-509761-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509761-21-00.